Published in Clin Cancer Res on December 03, 2010
Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med (2012) 1.61
Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res (2011) 1.31
Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin Cancer Res (2013) 1.05
Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res (2014) 0.96
Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res (2013) 0.95
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med (2014) 0.94
Reporting of preclinical tumor-graft cancer therapeutic studies. Cancer Biol Ther (2012) 0.85
Response of Merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor. PLoS One (2013) 0.83
Biology, models, and the analysis of tumor xenograft experiments. Clin Cancer Res (2011) 0.82
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia (2015) 0.80
Multi-parametric profiling network based on gene expression and phenotype data: a novel approach to developmental neurotoxicity testing. Int J Mol Sci (2011) 0.78
Patient-derived xenograft (PDX) tumors increase growth rate with time. Oncotarget (2016) 0.78
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies. Oncotarget (2015) 0.75
Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. Sci Rep (2016) 0.75
Modeling the tumor growth profiles in xenograft experiments--letter. Clin Cancer Res (2011) 0.75
Optimized design and analysis of preclinical intervention studies in vivo. Sci Rep (2016) 0.75
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res (2010) 2.34
Change points in the series of T4 counts prior to AIDS. Biometrics (1995) 1.58
The growth of transplanted murine tumours in pre-irradiated sites. Br J Cancer (1968) 1.48
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics (2002) 1.26
The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res (2001) 1.22
Modeling antitumor activity in xenograft tumor treatment. Biom J (2005) 1.03
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med (2005) 1.03
Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. Ann Epidemiol (2008) 1.00
Analysis of growth delay data: potential pitfalls. Br J Cancer Suppl (1980) 0.96
Eicosapentaenoic acid suppresses cell proliferation in MCF-7 human breast cancer xenografts in nude rats via a pertussis toxin-sensitive signal transduction pathway. J Nutr (2005) 0.96
Split dose recovery of a mouse tumour and its stroma during fractionated irradiation. Br J Radiol (1982) 0.91
Hierarchical models for tumor xenograft experiments in drug development. J Biopharm Stat (2004) 0.87
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys (2002) 3.64
Dose escalation of a curcuminoid formulation. BMC Complement Altern Med (2006) 3.59
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys (2006) 3.40
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res (2010) 2.34
Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2007) 2.33
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol (2005) 2.20
The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards. J Clin Oncol (2009) 1.88
Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer (2006) 1.83
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res (2004) 1.74
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res (2008) 1.68
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther (2009) 1.66
Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res (2005) 1.64
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res (2003) 1.62
Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med (2012) 1.61
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 1.60
Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol (2003) 1.60
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol (2007) 1.55
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol (2005) 1.54
Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol (2005) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
The application of lean thinking to the care of patients with bone and brain metastasis with radiation therapy. J Oncol Pract (2007) 1.48
Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem (2010) 1.46
NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res (2012) 1.46
An anaphylactoid reaction from amifostine. Radiother Oncol (2006) 1.42
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39
Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys (2008) 1.39
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Radiotherapy for locally advanced pancreatic cancer. J Clin Oncol (2007) 1.38
Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution. Int J Radiat Oncol Biol Phys (2009) 1.34
External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2006) 1.33
Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res (2011) 1.31
Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol (2009) 1.30
Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys (2004) 1.29
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res (2011) 1.29
Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys (2009) 1.28
Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res (2008) 1.26
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther (2004) 1.25
Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res (2010) 1.24
The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control (2008) 1.23
Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res (2006) 1.22
The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle (2006) 1.20
Global genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells. Cancer Biol Ther (2003) 1.20
Antimetabolite radiosensitizers. J Clin Oncol (2007) 1.20
Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.19
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer (2013) 1.16
Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg (2003) 1.16
The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res (2006) 1.15
Ablation of breast cancer stem cells with radiation. Transl Oncol (2011) 1.15
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2008) 1.14
Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys (2002) 1.14
Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res (2009) 1.13
SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB. J Cell Biol (2007) 1.11
Radiation produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and resistant mice. J Hematol Oncol (2009) 1.11
Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys (2005) 1.11
Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res (2002) 1.11
Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res (2010) 1.10
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res (2007) 1.09
The prediction of radiation-induced liver dysfunction using a local dose and regional venous perfusion model. Med Phys (2007) 1.09
Liver function after irradiation based on computed tomographic portal vein perfusion imaging. Int J Radiat Oncol Biol Phys (2007) 1.08
Diffusion tensor imaging of normal-appearing white matter as biomarker for radiation-induced late delayed cognitive decline. Int J Radiat Oncol Biol Phys (2011) 1.08
SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia (2005) 1.08
3H dendrimer nanoparticle organ/tumor distribution. Pharm Res (2004) 1.08
Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol (2007) 1.08
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for prediction of radiation-induced neurocognitive dysfunction. Clin Cancer Res (2009) 1.07
Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res (2008) 1.07
Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res (2008) 1.07